HC Wainwright Reiterates “Buy” Rating for ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $94.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 51.88% from the company’s previous close.

Several other analysts also recently weighed in on the company. Leerink Partners started coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. Finally, Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $77.71.

ANI Pharmaceuticals Trading Up 13.4 %

ANIP opened at $61.89 on Monday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock’s fifty day moving average is $57.23 and its two-hundred day moving average is $58.13. The company has a market capitalization of $1.30 billion, a P/E ratio of -112.53 and a beta of 0.74. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81.

Insider Transactions at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at $2,943,540. The trade was a 2.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,300 shares of company stock valued at $584,009. Corporate insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Millennium Management LLC raised its holdings in shares of ANI Pharmaceuticals by 89.3% in the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock worth $55,437,000 after buying an additional 473,097 shares during the last quarter. State Street Corp lifted its position in ANI Pharmaceuticals by 9.1% during the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock worth $41,991,000 after acquiring an additional 58,698 shares during the period. Dimensional Fund Advisors LP grew its stake in ANI Pharmaceuticals by 4.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company’s stock valued at $37,906,000 after purchasing an additional 30,420 shares during the last quarter. Deep Track Capital LP grew its stake in ANI Pharmaceuticals by 28.6% during the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company’s stock valued at $35,879,000 after purchasing an additional 144,214 shares during the last quarter. Finally, Global Alpha Capital Management Ltd. increased its holdings in shares of ANI Pharmaceuticals by 16.4% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company’s stock valued at $34,525,000 after purchasing an additional 88,100 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.